Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.53 |
| ▸ | HTR2A | P28223 | 8/20 | 0.53 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067525 | 1.00 | DRD3 (0.53) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL14715609 | 0.90 | HRH1 (0.45) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL3091198 | 0.90 | DRD3 (0.47) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL3080661 | 0.90 | DRD3 (0.49) | DRD3HTR2ADRD2 | |
| SCHEMBL3083297 | 0.90 | DRD3 (0.47) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL3075427 | 0.90 | DRD2 (0.56) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL3963444 | 0.90 | DRD2 (0.56) | DRD3HTR2ADRD2HRH1CCR3 | |
| SCHEMBL3067843 | 0.89 | DRD3 (0.53) | DRD3HTR2ADRD2 | |
| SCHEMBL3067847 | 0.89 | DRD3 (0.53) | DRD3HTR2ADRD2 | |
| SCHEMBL3082496 | 0.89 | DRD3 (0.42) | DRD3HTR2ADRD2HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | DRD3 71/4885HTR2A 565/4885DRD2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.